Stay updated with breaking news from Eric Ducournau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the...
Gennisium finds a strategic partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonato...
Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines
Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences
(0) BESTHESDA, Maryland and CASTRES, France, April 8, 2021 /PRNewswire/ -- The US biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre announced today the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease with unmet medical need. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside of oncology, the anti-IGF-1R antibody, discovered by Pierre Fabre at its Center of immunol...